Equities analysts forecast that KITOV PHARMA LT/S (NASDAQ:KTOV) will post ($0.01) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for KITOV PHARMA LT/S’s earnings. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that KITOV PHARMA LT/S will report full-year earnings of ($0.46) per share for the current year. For the next fiscal year, analysts expect that the business will report earnings of ($0.23) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow KITOV PHARMA LT/S.

Separately, Zacks Investment Research downgraded shares of KITOV PHARMA LT/S from a “hold” rating to a “sell” rating in a research note on Saturday.

Shares of KTOV stock opened at $1.13 on Monday. KITOV PHARMA LT/S has a 12 month low of $0.56 and a 12 month high of $3.81. The stock has a market cap of $17.81 million, a price-to-earnings ratio of 2.90 and a beta of 4.39.

KITOV PHARMA LT/S Company Profile

Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Featured Story: Cost of Goods Sold (COGS)

Get a free copy of the Zacks research report on KITOV PHARMA LT/S (KTOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.